[Four departments: Local health administration departments are not allowed to limit the number of total drug varieties and regulations in medical institutions. Class 1 new drugs in the two catalogs are not included in the "one product, two regulations"] On November 10, the National Health Commission, the National Medical Insurance Administration, the State Administration of Traditional Chinese Medicine, and the National Disease Control and Prevention Administration issued the "Notice on Further Improving the Safe and Reasonable Distribution and Use of Innovative Drugs" on the 10th. It is proposed that local health administrative departments shall not limit the number of total drug varieties and regulations in medical institutions, and new drugs in Category 1 in the two catalogs will not be included in the "one product, two regulations". Category 1 new drugs in the two catalogs are not included in the performance monitoring indicators of public medical institutions such as the proportion of essential drug prescriptions for outpatients, the utilization rate of essential drugs for inpatients, the proportion of essential drug procurement varieties, the increase in the average drug cost per outpatient visit, and the increase in the average drug cost per inpatient visit. Local health administrative departments should guide medical institutions to improve information systems and optimize internal management systems accordingly. Local health administrative departments and medical insurance departments should continue to strengthen policy publicity and implementation training, increase guidance and support for medical institutions within their jurisdictions, and increase the policy awareness rate of relevant medical institutions. It is necessary to regularly schedule the deployment and use of Class 1 new drugs in the two catalogs of relevant medical institutions in the jurisdiction to promote policy implementation. All localities should promote the deployment and use of innovative drugs in the two catalogs in accordance with the unified national deployment, and shall not use regional product catalogs to restrict the use of non-local products. The National Health Commission and the National Medical Insurance Administration will conduct surveys in due course to guide and supervise the safe and reasonable deployment and use of innovative drugs.